Revolutionary Brain Tumour Therapy Cuts Recurrence by 90% in Landmark Trial

A groundbreaking treatment for brain tumours has shown remarkable success in reducing recurrence and extending survival. Researchers at The University of Texas MD Anderson Cancer Center presented findings at the 2026 ASCO Annual Meeting, revealing that a novel radiation therapy delivered during surgery cuts local tumour return rates from 15.4% to just 1.3% after one year. The approach also more than doubles median survival times for patients.

The technique, called tile-based radiation therapy (TBRT), involves implanting tiny radioactive tiles directly into the surgical cavity after tumour removal. Early results suggest it could transform care for brain cancer patients while minimising side effects. TBRT works by embedding microscopic cesium-131 seeds inside bioresorbable collagen tiles, which are shaped to fit the tumour bed. These FDA-cleared devices deliver continuous, localised radiation to any remaining cancer cells immediately after resection. Unlike traditional stereotactic radiation therapy (SRT), which begins weeks later, TBRT exposes malignant cells to high doses before they can regrow or develop resistance.

The Phase 3 ROADS trial compared 250 patients receiving TBRT to 250 undergoing standard SRT. After one year, only 1.3% of TBRT patients experienced tumour recurrence at the surgical site, compared to 15.4% in the SRT group. Median overall survival jumped from 17.6 months with SRT to 42.5 months with TBRT. Treatment time also shrank dramatically—patients completed radiation in a single day instead of the 32 days required for SRT, allowing faster recovery and earlier follow-up therapies.

Safety data showed no increase in adverse effects with TBRT. Radiation necrosis rates remained nearly identical between the two methods, easing concerns about intraoperative radiation risks. The therapy’s design also limits exposure to surrounding healthy brain tissue, as its steep dose gradient targets only the immediate tumour area. This precision helps reduce neurotoxicity, a common challenge in brain cancer treatment.

Implementing TBRT requires close coordination between neurosurgeons, radiation oncologists, and medical physicists. The tiles must be custom-fitted to each patient’s tumour cavity during surgery, ensuring optimal radiation distribution. Researchers note that while the technique is currently focused on resectable brain metastases, its principles could eventually apply to primary brain tumours and other intracranial cancers. The trial’s outcomes position TBRT as a potential new standard for operable brain tumours. With recurrence rates slashed and survival times more than doubled, the therapy offers a compelling alternative to conventional radiation methods. Further studies may expand its use to other cancer types, though multidisciplinary teamwork will remain essential for successful adoption in clinical practice.